ArticleStem cells translational medicine2012
An abundant perivascular source of stem cells for bone tissue engineering.
Article in Stem cells translational medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed.
- Chondrogenic and Osteogenic In Vitro Differentiation Performance of Unsorted and Sorted CD34Journal of clinical medicine · 2025Article
- Serum metabonomics reveal the effectiveness of human placental mesenchymal stem cell therapy for primary sclerosing cholangitis.Stem cell research & therapy · 2024Article
- Repair of Rat Calvarial Critical-Sized Defects Using Heparin-Conjugated Fibrin Hydrogel Containing BMP-2 and Adipose-Derived Pericytes.Bioengineering (Basel, Switzerland) · 2024Article
- Specific lipid magnetic sphere sorted CD146-positive bone marrow mesenchymal stem cells can better promote articular cartilage damage repair.BMC musculoskeletal disorders · 2024Article
- The Therapeutic Potential of Pericytes in Bone Tissue Regeneration.Biomedicines · 2023Review
- Extent of Tissue Washing Can Significantly Alter the Composition of Adipose-Derived Stromal Vascular Fraction Cell Preparations: Implications for Clinical Translation.Stem cells translational medicine · 2023Article
- T-cadherin Expressing Cells in the Stromal Vascular Fraction of Human Adipose Tissue: Role in Osteogenesis and Angiogenesis.Stem cells translational medicine · 2022Article
- Versatile subtypes of pericytes and their roles in spinal cord injury repair, bone development and repair.Bone research · 2022Review
- Current evidence on potential of adipose derived stem cells to enhance bone regeneration and future projection.World journal of stem cells · 2021Review
- Article
- Novel cell sources for bone regeneration.MedComm · 2021Review
- Combined Biomaterials: Amniotic Membrane and Adipose Tissue to Restore Injured Bone as Promoter of Calcification in Bone Regeneration: Preclinical Model.Calcified tissue international · 2021Article
- Systemic DKK1 neutralization enhances human adipose-derived stem cell mediated bone repair.Stem cells translational medicine · 2021Article
- Deconstructing transcriptional variations and their effects on immunomodulatory function among human mesenchymal stromal cells.Stem cell research & therapy · 2021Article
- Human perivascular stem cells prevent bone graft resorption in osteoporotic contexts by inhibiting osteoclast formation.Stem cells translational medicine · 2020Article
- Lysosomal protein surface expression discriminates fat- from bone-forming human mesenchymal precursor cells.eLife · 2020Article
- Anti-DKK1 Enhances the Early Osteogenic Differentiation of Human Adipose-Derived Stem/Stromal Cells.Stem cells and development · 2020Article
- Comparison of skeletal and soft tissue pericytes identifies CXCR4Bone research · 2020Article
- Five Decades Later, Are Mesenchymal Stem Cells Still Relevant?Frontiers in bioengineering and biotechnology · 2020Review
- Skeletogenic Capacity of Human Perivascular Stem Cells Obtained Via Magnetic-Activated Cell Sorting.Tissue engineering. Part A · 2019Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Adipose tissue is an ideal mesenchymal stem cell (MSC) source, as it is dispensable and accessible with minimal morbidity. However, the stromal vascular fraction (SVF) of adipose tissue is a heterogeneous cell population, which has disadvantages for tissue regeneration. In the present study, we prospectively purified human perivascular stem cells (PSCs) from n = 60 samples of human lipoaspirate and documented their frequency, viability, and variation with patient demographics. PSCs are a fluorescence-activated cell sorting-sorted population composed of pericytes (CD45-, CD146+, CD34-) and adventitial cells (CD45-, CD146-, CD34+), each of which we have previously reported to have properties of MSCs. Here, we found that PSCs make up, on average, 43.2% of SVF from human lipoaspirate (19.5% pericytes and 23.8% adventitial cells). These numbers were minimally changed by age, gender, or body mass index of the patient or by length of refrigerated storage time between liposuction and processing. In a previous publication, we observed that human PSCs (hPSCs) formed significantly more bone in vivo in comparison with unsorted human SVF (hSVF) in an intramuscular implantation model. We now extend this finding to a bone injury model, observing that purified hPSCs led to significantly greater healing of mouse critical-size calvarial defects than hSVF (60.9% healing as opposed to 15.4% healing at 2 weeks postoperative by microcomputed tomography analysis). These studies suggest that adipose-derived hPSCs are a new cell source for future efforts in skeletal regenerative medicine. Moreover, hPSCs are a stem cell-based therapeutic that is readily approvable by the U.S. Food and Drug Administration, with potentially increased safety, purity, identity, potency, and efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.